🌐 EnglishEN

AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

🧪

Trial Match

Clinical trials test new treatments — sometimes the newest options available for a disease. Find trials that are recruiting now, near you. Open one to see its eligibility rules as simple questions to go through with your doctor.

Know your stage or your test results (such as EGFR, HER2 or BRCA)? Match trials to your own profile - nothing you type is saved.

🎯 Match trials to me

30 recruiting trials

for Metastatic Melanoma

A Randomized, Phase 2/3 Study to Investigate the Efficacy and Safety of RP2 in Combination With Nivolumab in Immune Checkpoint Inhibitor-Naïve Adult Patients With Metastatic Uveal Melanoma NCT06581406Phase 2, Phase 333 sites📍 Scottsdale📍 La Jolla📍 Los Angeles Replimune, Inc. · Tests: RP2, Ipilimumab, Nivolumab Immunotherapy Efficacy and PD-L1 as a Predictive Biomarker in Metastatic Melanoma in Slovenia NCT07422779NA1 site📍 Ljubljana Institute of Oncology Ljubljana · Tests: Pembrolizumab, Nivolumab, Ipilimumab Long-Term Follow-up of Patients Treated With Miltenyi Cell and Gene Therapies NCT06508775NA7 sites📍 Berlin📍 Cologne📍 Erlangen Miltenyi Biomedicine GmbH · Tests: MB-CART19.1, MB-CART20.1, MB-CART2019.1 Dual-Target CSPG4/GD2 CAR-NK Cells for Advanced Melanoma NCT07627698Phase 1, Phase 21 site📍 Shenzhen Beijing Biotech · Tests: EB-DTKN-401 allogeneic dual-target CSPG4/GD2 CAR-NK cells, Fludarabine, Cyclophosphamide Safety and Efficacy of OBX-115 in Advanced Solid Tumors NCT06060613Phase 1, Phase 210 sites📍 Los Angeles📍 Los Angeles📍 Stanford Obsidian Therapeutics, Inc. · Tests: OBX-115 Detection of the BRAF V600E Mutation in Liquid Biopsy Using the CRISPR/Cas12a System NCT07870265NA1 site📍 Brno Masaryk Memorial Cancer Institute · Tests: Novel CRISPR/Cas12a Electrochemical Bioassay, Reference Standard Molecular Diagnostics (NGS and ddPCR), Serial Peripher… Evaluation of the Safety, Efficacy, and Pharmacokinetics of NBM-BMX in Patients With Metastatic Uveal Melanoma NCT07136181Phase 1, Phase 23 sites📍 Scottsdale📍 Denver📍 Nashville Novelwise Pharmaceutical Corporation · Tests: NBM-BMX Capsule are proprietary products developed by Novelwise Pharmaceutical Corporation (Novelwise) for treatment of… To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma NCT06204991Phase 12 sites📍 Herlev📍 Herlev Inge Marie Svane · Tests: ADP-TILIL7, Cyclophosphamide, Fludarabine Phosphate, Proleukin Morning Versus Afternoon Administration of Immunotherapy for the Treatment of Advanced or Metastatic Solid Tumors, The Knight SHIFT Study NCT07405086Phase 41 site📍 Portland OHSU Knight Cancer Institute · Tests: Biospecimen Collection, Immune Checkpoint Inhibitor Anti PD-1 Plus Postbiotic Versus Anti PD-1 Alone in Locally Advanced or Metastatic, Treatment naïve, Cutaneous Melanoma Study NCT07050940NA5 sites📍 Bari📍 Torino📍 Bari Azienda Ospedaliera di Perugia · Tests: Postbiotic, AntiPD1 A Study of BMS-986504 Monotherapy and in Combination With Other Agents in Participants With Advanced and/or Metastatic Solid Tumors With Homozygous MTAP Deletion (MountainTAP-5) NCT07492680Phase 258 sites📍 San Francisco📍 Aurora📍 Atlanta Bristol-Myers Squibb · Tests: BMS-986504, Daraxonrasib, Nivolumab + Relatlimab FDC, Temozolomide, Pumitamig Avapritinib for the Treatment of CKIT or PDGFRA Mutation-Positive Locally Advanced or Metastatic Malignant Solid Tumors NCT04771520Phase 21 site📍 Houston M.D. Anderson Cancer Center · Tests: Avapritinib A Dose Escalation and Dose Expansion Study of Intratumoral ONM-501 Alone and in Combination With Cemiplimab in Patients With Advanced Solid Tumors and Lymphomas. NCT06022029Phase 116 sites📍 Los Angeles📍 Tamarac📍 Canton OncoNano Medicine, Inc. · Tests: ONM-501, Cemiplimab A Study of LN-144 or LN-145 in People With Advanced Uveal Melanoma, Undifferentiated Pleomorphic Sarcoma, Dedifferentiated Liposarcoma, or Angiosarcoma NCT05607095Phase 12 sites📍 Harrison📍 New York Memorial Sloan Kettering Cancer Center · Tests: Lifileucel (LN-144/LN-145) Beta Glucan's Effect on Pembrolizumab Immunologic Response in Stage III-IV Melanoma NCT04513028NA1 site📍 Louisville Kelly McMasters · Tests: Beta-Glucan Dabrafenib and/or Trametinib Rollover Study NCT03340506Phase 438 sites📍 Scottsdale📍 Bethesda📍 Columbus Novartis Pharmaceuticals · Tests: dabrafenib, trametinib 177Lu-anti-PD-L1 sdAb in Metastatic Solid Tumors NCT06305962EARLY Phase 15 sites📍 Kingswood📍 Wollongong📍 Southport Radiopharm Theranostics, Ltd · Tests: 177Lu-RAD204 RP1 in Primary Melanoma to Reduce the Risk of Sentinel Lymph Node Metastasis NCT06216938EARLY Phase 11 site📍 Pittsburgh Yana Najjar · Tests: Vusolimogene oderparepvec (RP1) Safety and Efficacy of EIK1001 in Combo With Pembro Versus Placebo and Pembro as First-Line Therapy in Patients With Advanced Melanoma. NCT06697301Phase 2, Phase 3127 sites📍 Chandler📍 Hot Springs📍 Los Angeles Eikon Therapeutics · Tests: EIK1001, Pembrolizumab (KEYTRUDA® ) IDOV-Immune for Advanced Solid Tumors NCT06910657Phase 15 sites📍 St Louis📍 Houston📍 San Antonio ViroMissile, Inc. · Tests: IDOV-Immune (oncolytic vaccinia virus) Anti-NY-ESO-1 TCR-Gene Engineered Lymphocytes Given by Infusion to Patients With NY-ESO-1 -Expressing Metastatic Cancers NCT05296564Phase 1, Phase 21 site📍 Jerusalem Hadassah Medical Organization · Tests: CYCLOPHOSPHAMIDE and FLUDARABIN, Cyclophosphamide, HBI 0201-ESO TCRT, Aldesleukin A Phase 1 Study of TGI-5 as Monotherapy and in Combination With Nivolumab in Subjects With Locally Advanced/Metastatic Solid Tumors NCT07376707Phase 11 site📍 Shanghai Hefei TG ImmunoPharma Co., Ltd. · Tests: TGI-5 Immune Response to Percutaneous Hepatic Perfusion With Melphalan for Ocular Melanoma Metastatic to the Liver NCT07364474NA1 site📍 Boston Massachusetts General Hospital · Tests: Melphalan through Percutaneous Hepatic Perfusion, Melphalan through Percutaneous Hepatic Perfusion in combination with … Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS NCT05379985Phase 1, Phase 221 sites📍 Orange📍 Santa Monica📍 Tampa Revolution Medicines, Inc. · Tests: RMC-6236 Study to Investigate Lifileucel Regimen Plus Pembrolizumab Compared With Pembrolizumab Alone in Participants With Untreated Advanced Melanoma. NCT05727904Phase 382 sites📍 Birmingham📍 Duarte📍 Los Angeles Iovance Biotherapeutics, Inc. · Tests: Lifileucel plus Pembrolizumab, Pembrolizumab with Optional Crossover Period Adjuvant Tebentafusp in High Risk Ocular Melanoma NCT06246149Phase 315 sites📍 Lake Success📍 Brussels📍 Nice European Organisation for Research and Treatment of Cancer … · Tests: Tebentafusp Follow-up of a National Cohort of Melanoma Resectable Stage II, Stage III or IV Patients or Unresectable Primary NCT02828202n/a27 sites📍 Amiens📍 Annecy📍 Besançon Assistance Publique - Hôpitaux de Paris · Tests: Biological, Tissular, Quality of life Nilotinib Plus Dabrafenib/Trametinib or Encorafenib/Binimetinib in Metastatic Melanoma NCT04903119Phase 14 sites📍 Iowa City📍 Lexington📍 Easton Rina Plattner · Tests: Nilotinib 100mg, Nilotinib 200mg, Nilotinib 300mg, Nilotinib 400mg, Dabrafenib Crizanlizumab Alone or in Combination With Nivolumab for Glioblastoma and Melanoma With Brain Metastases NCT05909618Phase 21 site📍 Ramat Gan Sheba Medical Center · Tests: Crizanlizumab-Tmca 10 MG/1 ML Intravenous Solution [ADAKVEO], Nivolumab 10 MG/1 ML Intravenous Solution [OPDIVO] Study of Adjuvant Darovasertib and Crizotinib in Participants With Primary Non-metastatic Uveal Melanoma NCT07804186Phase 313 sites📍 Scottsdale📍 Los Angeles📍 Boston IDEAYA Biosciences · Tests: Darovasertib, Crizotinib (Xalkori)
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy